Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study to Evaluate the Efficacy and Safety of Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer After Failure to First-line Platinum-based Chemotherapy

NCT03425201 is registered in ClinicalTrials.gov with Fundacion CRIS de Investigación para Vencer el Cáncer as lead sponsor.

NCT NCT03425201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03425201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study to Evaluate the Efficacy and Safety of Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer After Failure to First-line Platinum-based Chemotherapy
Lead sponsor
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase
Phase 1/2
Overall status
Completed
Start date
October 14, 2019
Completion date
July 31, 2024
Enrollment
67 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial cancer